SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
Adult
Age Factors
Antibodies, Viral
/ blood
Asymptomatic Infections
/ epidemiology
Bayes Theorem
Blood Donors
/ statistics & numerical data
COVID-19
/ epidemiology
COVID-19 Serological Testing
/ methods
Confidence Intervals
Cross-Sectional Studies
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Italy
/ epidemiology
Male
Middle Aged
Pandemics
Regression Analysis
Risk Factors
SARS-CoV-2
/ immunology
Seroconversion
Seroepidemiologic Studies
Spike Glycoprotein, Coronavirus
/ immunology
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
18
09
2020
accepted:
16
12
2020
pubmed:
5
2
2021
medline:
13
5
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
The Milan metropolitan area in Northern Italy was among the most severely hit by the SARS-CoV-2 outbreak. The aim of this study was to examine the seroprevalence trends of SARS-CoV-2 in healthy asymptomatic adults, and the risk factors and laboratory correlates of positive tests. We conducted a cross-sectional study in a random sample of blood donors, who were asymptomatic at the time of evaluation, at the beginning of the first phase (February 24 The test had a 100/98.3 sensitivity/specificity (n=32/120 positive/negative controls, respectively), and the IgG test was validated in a subset by an independent ELISA against the Spike protein (n=34, p<0.001). At the start of the outbreak, the overall adjusted seroprevalence of SARS-CoV-2 was 2.7% (95% CI: 0.3-6%; p<0.0001 vs 120 historical controls). During the study period, characterised by a gradual implementation of social distancing measures, there was a progressive increase in the adjusted seroprevalence to 5.2% (95% CI: 2.4-9.0; 4.5%, 95% CI: 0.9-9.2% according to a Bayesian estimate) due to a rise in IgG reactivity to 5% (95% CI: 2.8-8.2; p=0.004 for trend), but there was no increase in IgM SARS-CoV-2 infection was already circulating in Milan at the start of the outbreak. The pattern of IgM/IgG reactivity was influenced by age: IgM was more frequently detected in participants aged >45 years. By the end of April, 2.4-9.0% of healthy adults had evidence of seroconversion.
Sections du résumé
BACKGROUND
The Milan metropolitan area in Northern Italy was among the most severely hit by the SARS-CoV-2 outbreak. The aim of this study was to examine the seroprevalence trends of SARS-CoV-2 in healthy asymptomatic adults, and the risk factors and laboratory correlates of positive tests.
MATERIALS AND METHODS
We conducted a cross-sectional study in a random sample of blood donors, who were asymptomatic at the time of evaluation, at the beginning of the first phase (February 24
RESULTS
The test had a 100/98.3 sensitivity/specificity (n=32/120 positive/negative controls, respectively), and the IgG test was validated in a subset by an independent ELISA against the Spike protein (n=34, p<0.001). At the start of the outbreak, the overall adjusted seroprevalence of SARS-CoV-2 was 2.7% (95% CI: 0.3-6%; p<0.0001 vs 120 historical controls). During the study period, characterised by a gradual implementation of social distancing measures, there was a progressive increase in the adjusted seroprevalence to 5.2% (95% CI: 2.4-9.0; 4.5%, 95% CI: 0.9-9.2% according to a Bayesian estimate) due to a rise in IgG reactivity to 5% (95% CI: 2.8-8.2; p=0.004 for trend), but there was no increase in IgM
DISCUSSION
SARS-CoV-2 infection was already circulating in Milan at the start of the outbreak. The pattern of IgM/IgG reactivity was influenced by age: IgM was more frequently detected in participants aged >45 years. By the end of April, 2.4-9.0% of healthy adults had evidence of seroconversion.
Identifiants
pubmed: 33539289
pii: 2021.0324-20
doi: 10.2450/2021.0324-20
pmc: PMC8092034
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Spike Glycoprotein, Coronavirus
0
spike glycoprotein, SARS-CoV
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-189Références
Gastroenterology. 1996 Jan;110(1):178-83
pubmed: 8536854
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
J Viral Hepat. 2020 Aug;27(8):858-861
pubmed: 32196831
Nat Med. 2020 Jun;26(6):855-860
pubmed: 32322102
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mucosal Immunol. 2020 Jul;13(4):574-583
pubmed: 32157190
EBioMedicine. 2020 Nov;61:103069
pubmed: 33130396
Clin Microbiol Infect. 2020 Aug;26(8):1082-1087
pubmed: 32473953
J Clin Med. 2020 Oct 01;9(10):
pubmed: 33019628
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Vox Sang. 2020 Nov;115(8):603-605
pubmed: 32240543
Transfusion. 1997 Nov-Dec;37(11-12):1200-4
pubmed: 9426646
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Sci Total Environ. 2021 Jan 1;750:141711
pubmed: 32835962
Clin Chem Lab Med. 2020 Aug 26;58(12):2107-2111
pubmed: 32845861
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116